Clinical Trial for HHV-6 in CFS
Editor's note: This clinical trial focuses on treating HHV-6 in CFS patients. Meanwhile, AIDS patients are left to die from HHV-6 every single day because of the thuggish politics of HIV.
From the study:
"We hypothesized that a long course (i.e. 6 months) of valganciclovir could effectively decrease or stop ongoing viral replication of both EBV and HHV-6 and that this virological effect could be translated in a clinical and laboratory benefit (i.e. decrease or resolution of lymphadenopathy, reversion of the CD4/CD8 ratio abnormalities). We were surprised to see that a dramatic recovery on the level of physical activity was also observed in the Stanford patients (from a median of 10% of energy level for daily activities at baseline to 90% after valganciclovir use)." http://clinicaltrials.gov/ct/show/NCT00478465;jsessionid=E2B4EB
